Ardelyx, Inc. (NASDAQ:ARDX) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Ardelyx, Inc. (NASDAQ:ARDX) has earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $13.90.

Several analysts recently issued reports on ARDX shares. Piper Sandler reduced their price target on Ardelyx from $16.00 to $15.00 and set an “overweight” rating for the company in a research note on Monday, August 17th. TD Cowen lowered their price objective on Ardelyx from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ardelyx in a research report on Friday, September 25th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Ardelyx in a research report on Friday, August 7th. Finally, Citigroup dropped their price objective on shares of Ardelyx from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, August 10th.

Insider Activity at Ardelyx

In other news, insider Eric Foster sold 8,562 shares of Ardelyx stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $33,049.32. Following the completion of the sale, the insider directly owned 409,410 shares in the company, valued at approximately $1,580,322.60. The trade was a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael Raab sold 58,574 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $226,095.64. Following the completion of the sale, the chief executive officer owned 1,619,792 shares of the company’s stock, valued at approximately $6,252,397.12. This trade represents a 3.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 126,059 shares of company stock valued at $486,588. 5.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Ardelyx during the second quarter worth about $119,874,000. Jupiter Topco LLC bought a new position in Ardelyx in the 2nd quarter valued at about $27,043,000. AIGH Capital Management LLC bought a new position in Ardelyx in the 2nd quarter valued at about $16,320,000. Bank of America Corp DE raised its position in shares of Ardelyx by 5.8% in the 1st quarter. Bank of America Corp DE now owns 2,336,994 shares of the biopharmaceutical company’s stock valued at $13,999,000 after buying an additional 128,301 shares in the last quarter. Finally, Eversept Partners LP raised its position in shares of Ardelyx by 30.0% in the 1st quarter. Eversept Partners LP now owns 2,229,446 shares of the biopharmaceutical company’s stock valued at $13,354,000 after buying an additional 514,317 shares in the last quarter. Institutional investors own 58.92% of the company’s stock.

Key Stories Impacting Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Piper Sandler maintained its Buy rating on Ardelyx, signaling that the analyst continues to see potential upside despite recent volatility. Piper Sandler Reaffirms Their Buy Rating on Ardelyx
• Neutral Sentiment: Multiple law firms, including Rosen, Bronstein Gewirtz & Grossman, Pomerantz, and others, reminded investors of a November 16, 2026 lead-plaintiff deadline in a proposed securities class action covering purchases from January 13, 2025, through August 6, 2026. These announcements primarily repeat the same lawsuit and do not represent a court finding of wrongdoing. Rosen Securities Class Action Notice
• Negative Sentiment: The litigation alleges Ardelyx gave investors overly positive assurances about reimbursement conditions and pointed to approximately $1.75 billion in combined peak sales while payer restrictions allegedly hindered patient starts for IBSRELA and XPHOZAH. The allegations raise legal, reputational, and potential financial risks, weighing on investor sentiment. Ardelyx Investor Alert

Ardelyx Stock Up 2.2%

ARDX stock opened at $3.20 on Friday. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.69. The company has a fifty day moving average price of $3.54 and a two-hundred day moving average price of $4.93. Ardelyx has a one year low of $3.05 and a one year high of $8.40.

Ardelyx (NASDAQ:ARDX) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $120.88 million during the quarter, compared to analyst estimates of $121.03 million. Ardelyx had a negative net margin of 12.35% and a negative return on equity of 36.00%. Ardelyx’s revenue for the quarter was up 34.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.08) EPS. Equities analysts anticipate that Ardelyx will post -0.21 earnings per share for the current year.

About Ardelyx

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.

Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders.